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Summary 
Background  blockers reduce mortality in patients who have
chronic heart failure, systolic dysfunction, and are on
background treatment with diuretics and angiotensin-converting
enzyme inhibitors. We aimed to compare the effects of
carvedilol and metoprolol on clinical outcome.
Methods In a multicentre, double-blind, and randomised
parallel group trial, we assigned 1511 patients with chronic
heart failure to treatment with carvedilol (target dose 25 mg
twice daily) and 1518 to metoprolol (metoprolol tartrate, target
dose 50 mg twice daily). Patients were required to have chronic
heart failure (NYHA II–IV), previous admission for a cardio-
vascular reason, an ejection fraction of less than 0·35, and to
have been treated optimally with diuretics and angiotensin-
converting enzyme inhibitors unless not tolerated. The primary
endpoints were all-cause mortality and the composite endpoint
of all-cause mortality or all-cause admission. Analysis was done
by intention to treat.
Findings The mean study duration was 58 months (SD 6). The
mean ejection fraction was 0·26 (0·07) and the mean age 
62 years (11). The all-cause mortality was 34% (512 of 1511)
for carvedilol and 40% (600 of 1518) for metoprolol (hazard
ratio 0·83 [95% CI 0·74–0·93], p=0·0017). The reduction of all-
cause mortality was consistent across predefined subgroups.
The composite endpoint of mortality or all-cause admission
occurred in 1116 (74%) of 1511 on carvedilol and in 1160
(76%) of 1518 on metoprolol (0·94 [0·86–1·02], p=0·122).
Incidence of side-effects and drug withdrawals did not differ by
much between the two study groups.
Interpretation Our results suggest that carvedilol extends
survival compared with metoprolol.
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Introduction
Chronic heart failure is common,1 readily diagnosed, the
cause of disabling symptoms, has a poor prognosis, and
consumes about 2% of the total health budget in
developed countries.
Therapeutic strategies for chronic heart failure are based
on the notions of restriction of fluid retention and inhibition
of activation of neurohumoral systems, notably the renin-
angiotensin pathway and the sympathetic system. Guide-
lines recommend a combination of diuretics, angiotensin-
converting enzyme (ACE) inhibitors, and  blockers with or
without digoxin as a basis for treatment.2 Aldosterone
inhibitors are often used in patients with more severe heart
failure. Results of large clinical trials have shown that
although treatment with ACE inhibitors lessens admissions
and improves survival,3 morbidity and mortality remain
high. Addition of a  blocker further reduces mortality4–8
and has various effects on symptoms.9–11 Many mechanisms
for the benefits of these drugs have been put forward.
 blockers have different pharmacological profiles, for
example adrenergic receptor selectivity and the presence of
ancillary properties. Metoprolol and bisoprolol have a high
specificity for the -1 adrenergic receptor. Carvedilol blocks
-1, -2, and -1 adrenergic receptors.12 Bucindolol did not
have a mortality benefit in chronic heart failure.13 Results of
a meta-analysis14 suggested that carvedilol was associated
with a greater increase in left-ventricular ejection fraction
than metoprolol. Several other small studies12,15–17 have
suggested that carvedilol is more effective than metoprolol
in terms of remodelling and central haemodynamics, 
but the two drugs are similar in their effect on quality of
life10 or peak oxygen consumption.15,16 Carvedilol has several
other effects that might be advantageous in heart failure. 
It increases insulin sensitivity whereas metoprolol has 
the opposite effect.18 The antioxidant action of carvedilol19
might improve endothelial dysfunction and prevent
apoptosis, mechanisms that could be important in the
progression of chronic heart failure.20
We designed the Carvedilol Or Metoprolol European
Trial (COMET) to compare directly the effects of
carvedilol and metoprolol on mortality and morbidity in
patients with mild to severe chronic heart failure.
Methods 
Design
COMET was a multicentre, randomised, double-blind,
parallel-group trial to compare the effect on mortality and
morbidity of carvedilol and metoprolol in patients with
chronic heart failure. A detailed description of the study
design has been published, including the method of
randomisation, monitoring, and follow-up.21 The study was
done in 15 European countries, involving 341 centres, 
of which 317 contributed at least one patient. During the
trial one centre was withdrawn from the study because 
of irregularities. Recruitment began on Dec 1, 1996, 
and ended on Jan 15, 1999. Follow-up for mortality and
morbidity was concluded on Nov 15, 2002.
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Patients
Eligible patients were men or women with symptomatic
chronic heart failure (New York Heart Association
[NYHA] class II–IV), at least one cardiovascular admission
during the previous 2 years, on stable heart failure
treatment with ACE inhibitors for at least 4 weeks unless
contraindicated, and on treatment with diuretics (40 mg
of frusemide or equivalent) for at least 2 weeks. Digitalis,
angiotensin II inhibitors, or other vasodilators could be
used at the discretion of the investigators. 
Left-ventricular ejection fraction had to be 0·35 or 
lower measured within the previous 3 months by
echocardiography or radionuclide ventriculography. If the
ejection fraction was not determined, a left-ventricular end
diastolic diameter of greater than 6·0 cm and a fractional
shortening of less than 20% as measured by
echocardiography could qualify patients. 
Major exclusion criteria were a recent change of
treatment—defined as the introduction of a new class of
drug for heart failure or treatment with oral -adrenergic or
-adrenergic receptor blockers within the 2 weeks before
randomisation—requirement for intravenous inotropic
therapy, current treatment with calcium channel blockers
(of the diltiazem or verapamil class), amiodarone (>200 mg
per day) or class-I antiarrhythmic drugs, or administration
of any investigational drug within the preceding 30 days.
We excluded patients with unstable angina, myocardial
infarction, or coronary revascularisation or stroke within
the previous 2 months. Other exclusion criteria were
uncontrolled hypertension (blood pressure systolic >170
mm Hg or diastolic >105 mm Hg), haemodynamically
significant valvular disease, symptomatic and sustained
ventricular arrhythmias within the past 2 months not
adequately treated with antiarrhythmic drugs or
implantation of an automatic defibrillator, pregnancy,
women with childbearing potential on inadequate
contraception, known drug or alcohol misuse, poor
compliance with treatment or any other serious systemic
disease that might complicate management and reduce life
expectancy. 
We also excluded patients if there was a contraindication
to use of  blockers, such as resting heart rate of fewer than
60 beats per min, sick sinus syndrome, bifascicular block,
second or third degree atrioventricular block unless treated
with a pacemaker, sitting systolic blood pressure of less
than 85 mm Hg, history of asthma or chronic obstructive
pulmonary disease, peripheral arterial disease with
symptoms at rest, or unstable insulin-dependent diabetes
mellitus. 
The study conformed to good clinical practice guidelines
and followed the recommendations of the Declaration of
Helsinki. The protocol was approved by the relevant and
local ethics review boards. Written informed consent was
obtained from all patients before enrolment.
Procedures 
At randomisation, we assigned the 3029 eligible patients to
receive either 3·125 mg carvedilol twice daily or 5 mg
metoprolol tartrate twice daily. Randomisation was double
blind and used the method of permuted blocks by centre.
Investigators at each sites were supplied with numbered
treatment kits and instructed to take the lowest numbered
kit available for each new patient. Each kit contained
sufficient drugs to allow complete flexibility of treatment.
Patients entered initially a titration phase followed by a
maintenance period.
During the titration phase the dose of each  blocker was
increased to the target dose of carvedilol (25 mg twice
daily) or metoprolol (50 mg twice daily) every 2 weeks
according to the following schedules: 6·25 mg twice daily,
12·5 mg twice daily, and 25 mg twice daily for carvedilol,
and 12·5 mg twice daily, 25 mg twice daily, and 50 mg
twice daily for metoprolol. The investigator could modify
the dose regimen. If a patient did not tolerate an increase of
dose, a temporary decrease in dose was allowed.
Investigators were encouraged to adjust the dose of
diuretics and ACE inhibitors to increase the dose of the 
 blocker again towards the target dose. Subsequently
during the maintenance phase all patients were assessed
every 4 months until the end of the study. Patients
undergoing heart transplantation remained in the study
and were followed up in a manner identical to other
patients.
Safety was monitored by an independent data and safety
monitoring board. Adverse and serious adverse events were
reported to the study data centre. All reports of adverse
events were included irrespective of whether the
investigators thought they had been caused by the
treatment. Adverse events that were fatal or life-
threatening, required or extended admission, or resulted in
persistent or significant disability or incapacity were
labelled serious. All adverse events were coded, blinded to
treatment group, by a validated and established dictionary
that classifies events by major body systems. This
procedure identifies cardiovascular events.
All fatal events were adjudicated by the endpoint
committee masked to treatment status. We assigned mode
of death to one of five categories: sudden death, circulatory
failure, stroke, other cardiovascular death, and non-
cardiovascular death. Deaths that could not be classified
because of insufficient information were deemed
cardiovascular.
Statistical analysis
The study was planned as an event-driven parallel-group
survival study to compare carvedilol and metoprolol with
respect to all-cause mortality. In May, 2000, the steering
committee, who had no knowledge of the interim results or
treatment assignments, decided to add the composite
endpoint of all-cause mortality or all-cause admission as a
second primary endpoint. This endpoint had previously
been the first secondary endpoint specified by the protocol.
The change was made in recognition of the importance of
admission in this population and to ensure that COMET
had primary endpoints identical to those used in the
MERIT-HF study.6
With the introduction of the second primary endpoint,
we recalculated the required number of deaths. Although a
composite endpoint had been introduced it remained our
intention that the study be adequately powered to detect a
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3029 randomised
1511 assigned to carvedilol
          and received at least
          one tablet
10 withdrew consent
  3 lost to follow-up
1518 assigned to metoprolol
          and received at least
          one tablet
18 withdrew consent
  2 lost to follow-up
1511 assessed for primary
          endpoints
1518 assessed for primary
          endpoints
Figure 1: Trial profile
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mortality difference. 1020 fatal events were needed to
detect a risk reduction of 20% with at least 80% power.
This calculation reflected the following: premature end of
study treatment would reduce the anticipated risk
reduction in mortality by 20%, aggregate yearly mortality
would be 8·1% and the overall type I error of 0·05 would
be split—0·04 for all-cause mortality and 0·01 for the
composite endpoint. With respect to the composite
endpoint, about 2400 events were expected, giving 80%
power to detect a 15% reduction in risk at a significance
level of 0·01.
By the end of 2001, projections indicated that the
required number of deaths would occur by November,
2002. The steering committee declared that all patients
alive on Nov 15, 2002, would be administratively censored
on that date for the purpose of all efficacy analyses. By that
date 1112 patients had died.
Throughout the study, the data safety and monitoring
board did regular reviews for efficacy and safety. Since use
of  blockers for heart failure was quite new at the start of
the study, these reviews were scheduled for every
100 deaths. The protocol specified a fixed significance level
of 0·0001 (Peto rule22) as a guideline for stopping the study
at each interim analysis. However, the study finished as
planned without early termination. Formally, the
significance level for a comparison of treatments with
respect to mortality must be less than 0·039 to ensure that
the type I error for the study as a whole remains less than
0·05.
All randomised patients were included in the analysis of
both efficacy and safety by the intention-to-treat principle.
It was planned that all patients would be followed up to the
end of the study, even after study treatment ended
permanently. Some patients were lost to follow-up or
withdrew consent. These patients were censored at the last
known date of contact or date of withdrawal of consent,
respectively.
We analysed the primary endpoints with a log-rank test
without stratification. The relative risk (hazard ratio) and
95% CI were estimated with a Cox’s proportional hazard
model with treatment as the only covariate. Sensitivity
analyses to assess the robustness of the primary endpoint
results accounted for the effect of additional baseline
covariates and used a survival analysis with time-dependent
covariates to assess the relative contribution of study
treatments and any use of open-label  blockade after
previous end of study drugs.
Recorded survival times were well described by a
statistical model that assumed a constant hazard in each
treatment group (exponential survival). On this basis,
standard maximum likelihood methods were used to
obtain an estimate and a CI for the difference in median
survival between the treatments.
Role of the funding source
The trial was designed, overseen, implemented, and
assessed by an independent steering committee.
Representatives of the sponsor attended meetings of the
steering committee as non-voting members and in addition
the independent members met separately. The study
database is held by an independent data centre, the
Nottingham Clinical Research Group, Nottingham, 
UK. The data centre was also responsible for statistical
analysis of the data. Day to day operations were managed
initially by Boehringer Mannheim and later by 
F Hoffmann La Roche.
Results
Of 3029 patients, 1511 (50%) were assigned to treatment
with carvedilol and 1518 (50%) to metoprolol (figure 1).
The mean study duration was 58 months (SD 6). Five
patients were lost to follow-up and a further 28 patients
withdrew their consent to further follow-up during the
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Carvedilol Metoprolol 
(n=1511) (n=1518)
Age (years) 61·6 (11·3) 62·3 (11·4)
Male sex 1200 (79%) 1217 (80%)
White 1494 (99%) 1504 (99%)
Body-mass index (kg/m2) 26·9 (4·5) 26·8 (4·4)
Systolic blood pressure (mm Hg) 126 (19·3) 126 (19·7)
Diastolic blood pressure (mm Hg) 77 (11·0) 77 (10·9)
Heart rate (beats per minute) 81 (13·2) 81 (13·6)
NYHA class
II 730 (48%) 736 (49%)
III 732 (48%) 716 (47%)
IV 49 (3%) 66 (4%)
Duration congestive heart failure 42·6 (51·3) 42·2 (55·9)
(months)
Cause*
Ischaemic heart disease 776 (51%) 815 (54%)
Hypertension 270 (18%) 267 (18%)
Dilated cardiomyopathy 667 (44%) 663 (44%)
Previous valve surgery 43 (3%) 32 (2%)
Left-ventricular ejection fraction 0·26 (0·07) 0·26 (0·07)
NT-proBNP (g/L) 1298 (588–2792) 1185 (508–2670)
Previous myocardial infarction 626 (41%) 606 (40%)
CAD (confirmed by angiography) 550 (36%) 580 (38%)
Current angina 320 (21%) 331 (22%)
Previous angioplasty 122 (8%) 124 (8%)
Previous CABG 233 (15%) 282 (19%)
Hypertension 561 (37%) 540 (36%)
Diabetes 360 (24%) 370 (24%)
Stroke 106 (7%) 108 (7%)
Electrocardiographic findings*
Sinus rhythm 1124 (74%) 1135 (75%)
Atrial fibrillation/flutter 309 (21%) 291 (19%)
Paced rhythm 90 (6%) 108 (7%)
LBBB 88 (6%) 79 (5%)
Concomitant drugs at randomisation
Diuretics† 1494 (99%) 1496 (99%)
ACE inhibitors† 1383 (92%) 1384 (91%)
Angiotensin receptor antagonists 94 (6%) 104 (7%)
Digitalis 916 (61%) 884 (58%)
Antiarrhythmics 189 (13%) 179 (12%)
Nitrates 494 (33%) 498 (33%)
Aldosterone antagonists 164 (11%) 163 (11%)
 blockers‡ 64 (4%) 66 (4%)
Anticoagulants 723 (48%) 662 (44%)
Aspirin 528 (35%) 588 (39%)
Lipid lowering agents (statins) 308 (20%) 331 (22%)
NT-proBNP=N-terminal probrain natriuretic peptide. CAD=coronary artery disease.
CABG=coronary artery bypass graft. LBBB=Left-bundle branch block.
ACE=angiotensin-converting enzyme. Data are mean (SD), median (range), or
number of patients (%). *More than one answer possible. †Inclusion criteria.
‡Stopped before study start.
Table 1: Baseline characteristics
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Figure 2: All-cause mortality
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course of the study. All other patients were followed up to
death or study end. 
Table 1 shows the baseline characteristics. The mean age
was 62 years (11) and the mean ejection fraction 0·26
(0·07). Patients were evenly distributed between NYHA II
and III.  
Figure 2 shows the Kaplan-Meier estimates of all-cause
mortality for each treatment. 512 people in the carvedilol
group died compared with 600 in the metoprolol 
group, giving a hazard ratio of 0·83 (95% CI 0·74–0·93,
p=0·0017) in favour of carvedilol. The mortality benefit
became apparent at about 6 months. The reduction 
in all-cause mortality was similar in direction and in
magnitude across the predefined subgroups (figure 3). 
In addition, sensitivity analyses confirmed the primary
mortality analysis. The difference remained after
adjustment for known prognostic factors. The on-
treatment analysis showed a hazard ratio of 0·77
(0·67–0·90, p=0·0008) in favour of the carvedilol group.
Although the number of deaths differed between groups,
the distribution of mode of death was much the same for
the two treatments. Sudden death was the adjudicated
mode of death for 218 patients (14%) in the carvedilol
group and in 262 (17%) patients in the metoprolol group—
43% of all deaths in the carvedilol group and 44% in the
metoprolol group. 33% of all deaths in both groups (n=168
for carvedilol and n=197 for metoprolol) were due to
circulatory failure.
There were 438 cardiovascular deaths in the carvedilol
group and 534 in the metoprololol group (table 2). 
28 patients in the carvedilol group and 27 in the metoprolol
group underwent heart transplantation. 
1116 patients in the carvedilol group and 1160 in the
metoprolol group died or were admitted (table 2). The
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Figure 3: All-cause mortality by predefined subgroups
Points are hazard ratios (HR) and lines are 95% CI. NYHA=New York Heart Association. IHD=ischaemic heart disease. LVEF=left-ventricular ejection
fraction. BP=blood pressure.
Carvedilol (n=1511) Metoprolol (n=1518) Hazard ratio (95% CI) p
All deaths 512 (34%) 600 (40%) 0·83 (0·74–0·93) 0·002
5 year Kaplan-Meier 35·3% 41·0% ·· ··
Time at risk (months) 46·8 (18·9) 45·2 (19·5) ·· ··
Yearly mortality rate 8·3 10·0 ·· ··
Cardiovascular deaths 438 (29%) 534 (35%) 0·80 (0·70–0·90) 0·0004
Non-cardiovascular deaths 74 (5%) 66 (4%) 1·08 (0·77–1·50) ··
All deaths and all-cause admission* 1116 (74%) 1160 (76%) 0·94 (0·86–1·02) 0·122
5 year Kaplan-Meier 75·5% 78·5% ·· ··
Time at risk (months) 27·1 (22·7) 25·9 (22·1) ·· ··
First event admission 1022 (68%) 1031 (68%) ·· ··
First event death 94 (6%) 129 (8%) ·· ··
Data are number of deaths (%) or mean (SD). *Any patient counted once only.
Table 2: Primary endpoints and components of the composite endpoint
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hazard ratio for total admission alone was 0·97 (95% CI
0·89–1·05, p=0·45) so that the composite endpoint was
driven mainly by mortality.
The mean daily dose at entry into the maintenance phase
in the carvedilol group (n=1308) was 41·8 mg 
(SD 14·6) a day, with 1140 (87%) patients taking 25 mg a
day or more, and 980 (75%) receiving the target dose of 
25 mg twice a day. In the metoprolol group (n=1317) the
mean daily dose was 85 mg a day (SD 28·9), 1146 (87%)
taking 50 mg a day or more, and 1019 (78%) receiving the
target dose of 50 mg twice a day.
The mean baseline heart rates were identical (table 1).
After 4 months of treatment, mean heart rate on treatment
had decreased from baseline by 13·3 beats per min in the
carvedilol group and by 11·7 beats per min in the
metoprolol group (difference –1·6 beats per min, 
95% CI –2·7 to –0·6). The change in heart rate for all
patients over the period of the trial is shown in figure 4.
The heart rate did not differ after 16 months. At 4 months,
patients mean decrease of systolic blood pressure from
baseline was 3·8 mm Hg (SD 17·4) in the carvedilol group
and 2·0 mm Hg (SD 17·7) in the metoprolol group
(difference –1·8 mm Hg, 95% CI –3·2 to –0·4).
The study drug was permanently stopped for reasons
other than death in 481 (32%) patients in the carvedilol
group and in 483 (32%) in the metoprolol group. Reasons
for permanent cessation of treatment were similar in the
two groups, as were the distributions of time on treatment.
In the carvedilol group 80·5% of the survival time was
spent on the study drug, compared with 81·5% in the
metoprolol group. The proportion of patients who had
adverse events or serious adverse events and the number of
events were fewer in the carvedilol group than the
metoprolol group despite differences in mortality leading to
a slightly longer mean observation time of 46·8 months
(SD 18·9) compared with 45·2 months (19·5) for
metoprolol (tables 2 and 3). The pattern of adverse events
usually associated with  blockade was similar in the two
groups. Bradycardia was reported in 144 (10%) patients in
the carvedilol group and in 135 (9%) patients in the
metoprolol group. Bradycardia was a serious adverse event
in 3% of patients in both groups (n=39 with carvedilol and
n=40 with metoprolol). Hypotension was reported in 215
(14%) patients in the carvedilol group and in 160 (11%)
patients in the metoprolol group. Hypotension was a
serious adverse event in 48 (3%) and in 29 (2%) of
patients, respectively.
Discussion
Our results suggest that carvedilol used for treatment of
chronic heart failure, in patients optimally treated with
diuretics and ACE inhibitors, has a significantly greater
beneficial effect on survival than metoprolol. The absolute
reduction in mortality over 5 years was 5·7%. Survival times
were consistent with a constant hazard in each 
group permitting estimation of median survival.
Extrapolation from the survival curves suggested that
carvedilol extended median survival by 1·4 years (95% CI
0·5–2·3) as compared with metoprolol (estimated median
survival on carvedilol 8·0 years [95% CI 7·3–8·7], on
metoprolol 6·6 years [6·1–7·1]). The calculated number of
patient-years of treatment to save one life is 59,23 which is
similar to the effect of an ACE inhibitor or selective -1
blocker versus placebo in comparable patient populations.
The findings were consistent across predefined subgroups.
Sensitivity analyses confirmed that the finding was robust
and was not affected by variables such as the number of
patients lost to follow-up or who withdrew consent. The
patients included in the study had mild to severe heart
failure (NYHA II–IV) and similar baseline characteristics to
patients in earlier trials of  blockers in heart failure.5,6 The
yearly mortality rate was 8·3% for carvedilol and 10·0% for
metoprolol. The yearly mortality rate in MERIT-HF6 was
7·2% in the group given metoprolol, and in CIBIS-II5 the
rate was 8·8% in the group given bisoprolol.
The composite endpoint of all-cause mortality and all-
cause admission, although numerically in favour of
carvedilol, was not significant. Withdrawals from the trial,
excluding death, were almost identical. It is uncommon in
clinical trials to find no significant treatment difference
with respect to a composite endpoint, but a clear difference
in one component such as mortality.24 The benefit of
carvedilol in this trial was thus driven by 
the reduction in mortality. The effect of carvedilol seems to
be on a mechanism of death rather than on the
determinants of admissions. The hazard reduction for
cardiovascular mortality was 20%.
 blockers were first advocated for treatment of 
heart failure in 1975.25 Results of large clinical trials
subsequently showed that carvedilol,4,7 metoprolol,6 and
bisoprolol5 reduce mortality when added to conventional
therapy. A trial with bucindolol13 was not successful. The 
blockers proven to be effective differ by their adrenergic
receptor selectivity and their ancillary properties. The
results of our study together with those of other studies
showing varying degrees of benefit and harm indicate that
these differences are important for clinical outcomes.
Results of several small studies have shown favourable
effects of carvedilol compared with metoprolol in terms of
haemodynamics but similar effects on quality of life.10,12,15–17
We began the trial in 1996 in response to the findings of
earlier studies,4,26 but, during the course of the trial both of
the drugs being compared had a favourable effect on
mortality.6,7
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Figure 4: Heart rate at each visit on treatment
Error bars are 1 SE. *p=0·0022. †p=0·0034. ‡p=0·0040.
Carvedilol Metoprolol 
(n=1511) (n=1518)
Patients with at least one adverse event 94% 96%
Number of adverse events 8469 8808
Patients with at least one cardiovascular adverse 74% 76%
event
Number of cardiovascular events 3529 3642
Patients with at least one serious adverse event 75% 77%
Number of serious adverse events 4035 4184
Patients with at least one serious 55% 57%
cardiovascular adverse event
Number of serious cardiovascular events 2111 2265
Values are number of patients (%) or number of events.
Table 3: Safety variables
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In a large mortality study comparing two drugs, a
decision has to be made about dose. The steering
committee selected 25 mg twice daily for carvedilol and 50
mg twice daily for metoprolol to be used as target doses in
COMET to achieve a comparable degree of 
 blockade in both groups.21 The evidence suggested that a
dose ratio of 2 to 1 would achieve similar reductions in
heart rate. In the Metoprolol Dilated Cardiomyopathy
(MDC) trial26 the target dose for metoprolol was 
100–150 mg daily. The actual mean dose was 108 mg (SD
51) daily and the mean heart rate reduction was 15 beats
per min. In the US carvedilol study4 the mean daily dose
was 45 mg (SD 27) and heart rate was reduced by 13 beats
per min. The target dose of carvedilol in COPERNICUS7
was 25 mg twice daily and the actual mean dose 37 mg
daily.
In 1988, Sandberg and colleagues27 compared a new
multiple-unit, controlled release formulation of metoprolol,
metoprolol succinate (metoprolol CR/XL), with the
conventional metoprolol tartrate tablets in patients with
heart failure and showed that the formulation showed a
30–35% reduced systemic availability. When COMET was
started, this preparation was not available to us. The target
dose used in MERIT-HF (200 mg metoprolol succinate) is
equivalent to about 130 mg of the salt (metoprolol tartrate)
used in COMET. In MERIT-HF the actual mean dose
was 159 mg once daily (equivalent to 106 mg of metoprolol
tartrate) and the reduction of heart rate 14 beats per min.
In a post-hoc analysis of data from MERIT-HF28 the risk
reduction for mortality was identical in two groups
analysed according to titrated dose (100 mg daily, and
>100 mg daily), which achieved mean doses of metoprolol
succinate of 76 mg and 192 mg once daily, respectively.
These doses are equivalent to 51 mg and 128 mg
metoprolol tartrate, respectively. The on-treatment
reductions of heart rate were 14 beats per min and 16 beats
per min, respectively at 3 months. In COMET the mean
doses at the onset of the maintenance phase were for
carvedilol 42 mg daily and for metoprolol 85 mg daily. The
respective reductions of heart rate from an on-treatment
analysis were 13·3 beats per min and 11·7 beats per min.
After 16 months there were no differences (figure 4). In
CIBIS II29 bisoprolol caused a mean reduction in heart rate
of 10 beats per min at 2 months. The outcome of COMET
is unlikely to be attributable to an effect of dose because of
the comparability of the two doses as assessed from other
studies, the flat dose-response to metoprolol in terms of
heart rate and outcomes,28 and the similar reduction of
heart rate in the two groups. The small differences in the
fall of heart rate in the first 16 months of the trial do not
necessarily indicate a different degree of  blockade. The
antagonistic effect of carvedilol on -2 and -adrenergic
receptors might have a discernible effect on heart rate 
and blood pressure. Clinical trials rarely establish a
mechanism for any effect observed. The favourable
outcome with carvedilol could be attributed to blockade of
both -1 and -2 adrenergic receptors, inhibition of 
-adrenergic receptors, a greater anti-ischaemic effect,
inhibition of apoptosis, an antioxidant action, free radical
scavenging, or an electrophysiological effect.
Three  blockers have been shown to confer benefit on
patients with chronic heart failure. Metoprolol and
bisoprolol are selective -1 adrenergic receptor inhibitors.
No previous comparisons of  blocking drugs with
different properties on long-term mortality and morbidity
have been made in patients with heart failure. The results
of this study show that carvedilol extends survival by
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